• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

bioAffinity Technologies, Inc. - Common Stock (NQ:BIAF)

6.055 -0.090 (-1.46%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about bioAffinity Technologies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL
September 30, 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference
September 22, 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic
September 17, 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
September 09, 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 03, 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
Catalysts Emerge BIAF, LIDR, SSM, GMGMF to Watch Now
September 01, 2026
Via AB Newswire
Topics Artificial Intelligence
News headline image
bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors
September 01, 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026
August 20, 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
Algorhythm Holdings (NASDAQ: RIME) Volume Surges as Q2 Revenue Jumps 161%, Potential Oversold Setup Emerges
August 18, 2026
Via AB Newswire
Topics Artificial Intelligence
News headline image
bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung
August 18, 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
August 14, 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
August 13, 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung
August 07, 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung
July 27, 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD
July 22, 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues
July 07, 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
Q2 Virtual Investor Summit Presentations Now Available On Demand
June 30, 2026
From Investor Summit Group
Via ACCESS Newswire
News headline image
bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells
June 22, 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Closing of $3.2 Million Offering
June 18, 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Pricing of $3.2 Million Offering
June 17, 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Program to Advance Veteran Lung Health: Philips, bioAffinity Technologies and 4DMedical Highlight New Approaches to Lung Health Screening for U.S. Veterans
June 16, 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar
June 02, 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung Technology
May 27, 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026
May 12, 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung
May 08, 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment
April 28, 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
New Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy
April 14, 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16
April 07, 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026
April 01, 2026
From bioAffinity Technologies, Inc.
Via Business Wire
News headline image
bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice
March 25, 2026
From bioAffinity Technologies, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap